Asset Details
Do you wish to reserve the book?
Triamcinolone Acetonide Extended-Release: A Review in Osteoarthritis Pain of the Knee
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Triamcinolone Acetonide Extended-Release: A Review in Osteoarthritis Pain of the Knee
Do you wish to request the book?
Triamcinolone Acetonide Extended-Release: A Review in Osteoarthritis Pain of the Knee
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Triamcinolone Acetonide Extended-Release: A Review in Osteoarthritis Pain of the Knee
2019
Overview
Triamcinolone acetonide extended-release (ER) 32 mg (Zilretta
®
) is approved in the USA for the management of osteoarthritis (OA) pain of the knee and is administered as a single, 5 mL intra-articular (IA) injection. Although the therapeutic effects from IA corticosteroids are typically short-lived, triamcinolone acetonide ER is formulated in poly (lactic-co-glycolic acid) (PLGA) microspheres that slowly release triamcinolone acetonide in the synovium, enabling their prolonged presence in the joint. This reduces systemic exposure and lessens corticosteroid-related systemic adverse reactions, such as blood glucose elevations. In a 24-week, randomized, phase III clinical trial, triamcinolone acetonide ER 32 mg significantly improved mean average daily pain intensity in patients with knee OA relative to placebo, and pain, stiffness and physical function (according to WOMAC criteria) relative to placebo and triamcinolone acetonide crystalline suspension (CS). Triamcinolone acetonide ER was generally well tolerated, with a tolerability profile similar to that of triamcinolone acetonide CS and placebo. Findings from a single-arm phase IIIb study indicated that a repeat administration of triamcinolone acetonide ER may be similarly efficacious to an initial injection without having deleterious effects on cartilage or other aspects of joint structure. Thus, triamcinolone acetonide ER expands the treatment options available for the management of OA pain of the knee.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
/ Clinical Trials, Phase III as Topic
/ Delayed-Action Preparations - adverse effects
/ Delayed-Action Preparations - therapeutic use
/ Diabetes
/ Humans
/ Knee
/ Medicine
/ Osteoarthritis, Knee - drug therapy
/ Pain
/ Polylactic Acid-Polyglycolic Acid Copolymer - chemistry
/ Randomized Controlled Trials as Topic
/ Synovial Membrane - drug effects
/ Synovium
/ Triamcinolone Acetonide - adverse effects
